Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isentress

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

- PMLiVE

Gilead and Aelix join forces to pursue HIV ‘cure’

The HTI vaccine could replace antiretroviral therapy if it reaches market

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

ViiV chalks up another win for two-drug HIV regimen

Once a month injection matches triple oral therapy

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

- PMLiVE

Daily Brief: Janssen’s HIV vaccine, Q2 results, Biogen’s Alzheimer’s data

News from pharma, biotech and healthcare

- PMLiVE

Trial data suggest Abivax’ drug may clear latent HIV

The drug reduced HIV DNA in cells over 28 days

- PMLiVE

90TEN celebrates double win for HIV campaign at Communiqué 2018

Agency wins two awards for bold My Journey: Flight HIV101 campaign

Gilead Sciences

Gilead’s Biktarvy gets European approval, setting up battle with GSK

The drug could offset Gilead's disappointing hep C franchise

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links